HR Execs on the Move

Cbd Ophthalmic

www.cbdophthalmic.com

 
Cbd Ophthalmic is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

WS Audiology

Formed in 2019, through the merger of Sivantos and Widex, WS Audiology combines more than 140 years experience in pioneering the use of technology to help people with hearing loss hear the sounds that make life wonderful. Today, one out of three hearing aids is made by us and we are active in over 125 markets, employing close to 12,000 people worldwide. Our broad portfolio of leading hearing-related products and services generates annual revenues of more than € 2 billion. WS Audiology is privately owned by the Tøpholm and Westermann families, as well as funds under the management of EQT. As a global leader, our ambition is to unlock human potential by making wonderful sound part of everyone`s life.

STS Life Sciences Division, Ethox International

STS Life Sciences Division, Ethox International is a Rush, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medlink Imaging

Medlink Imaging is a Teterboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ENPRO

ENPRO is a Addison, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.